Annalisa Trama, Giuseppe Lo Russo, Monica Ganzinelli, Laura Abate-Daga, Tommaso Martino De Pas, Paolo Mendogni, Rossana Berardi, Davide Franceschini, Lorenzo Rosso, Giovannella Palmieri, Iacopo Petrini, Giulia Pasello, Fiorella Calabrese, Giovanni Maria Comacchio, Fabiana Letizia Cecere, Mirella Marino, Enrico Ruffini, Marina Chiara Garassino, Paraskevas Lyberis, Andrea Dell'Amore, Giulia Galli, Paolo Andrea Zucali
{"title":"From fragmentation to focus: building collaborative networks for rare cancer research - the Italian TYME network as a model for care and innovation?","authors":"Annalisa Trama, Giuseppe Lo Russo, Monica Ganzinelli, Laura Abate-Daga, Tommaso Martino De Pas, Paolo Mendogni, Rossana Berardi, Davide Franceschini, Lorenzo Rosso, Giovannella Palmieri, Iacopo Petrini, Giulia Pasello, Fiorella Calabrese, Giovanni Maria Comacchio, Fabiana Letizia Cecere, Mirella Marino, Enrico Ruffini, Marina Chiara Garassino, Paraskevas Lyberis, Andrea Dell'Amore, Giulia Galli, Paolo Andrea Zucali","doi":"10.1080/14737140.2026.2723471","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Rare cancers, individually uncommon but collectively significant, pose major challenges due to their heterogeneity, low incidence, and fragmented expertise. This review addresses the complexities of managing and researching rare cancers, highlighting the necessity for collaborative networks.</p><p><strong>Areas covered: </strong>A systematic literature search was conducted using PubMed to identify peer-reviewed articles from 2010 to 2025 focusing on rare cancers, collaborative clinical networks, European Reference Networks (ERNs), and thymic malignancies. The review examines key obstacles such as limited patient populations, uneven expertise distribution, funding challenges, and explores models of collaboration including ERNs and the Italian TYME network. These networks exemplify integrated efforts to improve clinical care, research efficiency, and patient involvement through coordinated governance, registries, and multidisciplinary approaches.</p><p><strong>Expert opinion: </strong>Sustainable, transparent, and inclusive collaborative networks like TYME and ERNs are essential to overcoming rare cancer research barriers. They enable standardized care, robust data sharing, and enhanced clinical trials, ultimately improving outcomes. Continued investment, policy support, and expansion of interoperable digital infrastructures are critical to fully realize the transformative potential of these network models in rare cancer care.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":3.0000,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2026.2723471","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Rare cancers, individually uncommon but collectively significant, pose major challenges due to their heterogeneity, low incidence, and fragmented expertise. This review addresses the complexities of managing and researching rare cancers, highlighting the necessity for collaborative networks.
Areas covered: A systematic literature search was conducted using PubMed to identify peer-reviewed articles from 2010 to 2025 focusing on rare cancers, collaborative clinical networks, European Reference Networks (ERNs), and thymic malignancies. The review examines key obstacles such as limited patient populations, uneven expertise distribution, funding challenges, and explores models of collaboration including ERNs and the Italian TYME network. These networks exemplify integrated efforts to improve clinical care, research efficiency, and patient involvement through coordinated governance, registries, and multidisciplinary approaches.
Expert opinion: Sustainable, transparent, and inclusive collaborative networks like TYME and ERNs are essential to overcoming rare cancer research barriers. They enable standardized care, robust data sharing, and enhanced clinical trials, ultimately improving outcomes. Continued investment, policy support, and expansion of interoperable digital infrastructures are critical to fully realize the transformative potential of these network models in rare cancer care.
期刊介绍:
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.